+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

F

Actively Recruiting

Researchers are conducting an ongoing international observational program called the Fabry Registry to track routine clinical outcomes in patients diagnosed with Fabry disease. This registry includes all patients regardless of their treatment status and aims to improve understanding of the diseases variability, progression, and natural history, including in female patients. It also supports development of monitoring recommendations, characterization of the Fabry population, and evaluation of the long-term safety and effectiveness of Fabrazyme4. The study features a Fabry Pregnancy Sub-registry, which observes pregnancy outcomes in women enrolled in the main registry. This sub-registry collects data on medical and obstetric history, pregnancy, birth outcomes, and infant growth up to 36 months postpartum. Neither the main registry nor the pregnancy sub-registry involve experimental interventions, and patients receive standard care as determined by their treating physicians. Participants undergo clinical assessments and receive their usual care during the registry. Data collected includes safety and effectiveness of treatments like Fabrazyme4 over long periods, as well as pregnancy complications and infant growth measurements. The study is designed to last until 2034, with ongoing monitoring and data collection to support patient care and research without altering treatment plans.

All AgesAll Genders
284 locations
L

Actively Recruiting

Researchers are evaluating the long-term safety and tolerability of zigakibart in adults with primary immunoglobulin A nephropathy IgAN. This open-label extension study includes participants who have completed previous zigakibart trials, aiming to gather extended safety information and assess the drugs effects over time. The study is sponsored by Novartis Pharmaceuticals and continues from earlier phase 12 and phase 3 studies. Participants will receive zigakibart as a solution for subcutaneous injection at a dose of 600 mg every two weeks. This is a single-group, open-label study where all participants receive the active treatment. The study monitors safety and tolerability through various assessments over several years, including serum drug levels and immunoglobulin measurements. Participants are followed for up to approximately five years to observe any adverse events and changes in kidney function. During the study, participants will have scheduled visits for clinical evaluations, laboratory testing, and monitoring of adverse events. Key measurements include urinary protein to creatinine ratio UPCR, estimated glomerular filtration rate eGFR, immunoglobulin levels, and detection of anti-drug antibodies. Safety labs and vital signs will be tracked throughout. The studys main outcomes focus on the number of participants experiencing adverse events, with follow-up continuing 24 weeks after treatment ends. Overall participation may last up to six years, including treatment and post-treatment monitoring.

Age: 18Years - 100YearsAll GendersPhase 3
26 locations